相似文献
1
Central neurotoxicity of immunomodulatory drugs in multiple myeloma.
Hematol Rep. 2015 Mar 3;7(1):5704. doi: 10.4081/hr.2015.5704. eCollection 2015 Feb 24.
2
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Curr Cancer Drug Targets. 2017;17(9):846-857. doi: 10.2174/1568009617666170214104426.
3
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17.
4
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Leuk Lymphoma. 2016 Nov;57(11):2510-5. doi: 10.3109/10428194.2016.1151507. Epub 2016 Mar 4.
5
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Leuk Lymphoma. 2011 Apr;52(4):560-6. doi: 10.3109/10428194.2011.552139. Epub 2011 Feb 21.
6
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6.
7
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
Life (Basel). 2023 Nov 20;13(11):2229. doi: 10.3390/life13112229.
8
Immunomodulatory drugs in the treatment of multiple myeloma.
Jpn J Clin Oncol. 2019 Aug 1;49(8):695-702. doi: 10.1093/jjco/hyz083.
9
Novel immunomodulatory compounds in multiple myeloma.
Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25.
10
[Immunomodulator drugs for the treatment of multiple myeloma].
Rev Med Chil. 2018 Dec;146(12):1444-1451. doi: 10.4067/s0034-98872018001201444.
引用本文的文献
1
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System.
Pharmaceuticals (Basel). 2024 Sep 25;17(10):1266. doi: 10.3390/ph17101266.
2
Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents.
Antibiotics (Basel). 2023 Nov 23;12(12):1651. doi: 10.3390/antibiotics12121651.
3
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.
Onco Targets Ther. 2022 Sep 6;15:953-962. doi: 10.2147/OTT.S365657. eCollection 2022.
4
Current status and future directions for a neurotoxicity hazard assessment framework that integrates approaches.
Comput Toxicol. 2022 May;22. doi: 10.1016/j.comtox.2022.100223. Epub 2022 Mar 17.
5
Managing treatment-related peripheral neuropathy in patients with multiple myeloma.
Blood Lymphat Cancer. 2016 Jun 29;6:37-47. doi: 10.2147/BLCTT.S91251. eCollection 2016.
6
Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos.
Front Pharmacol. 2019 Apr 17;10:349. doi: 10.3389/fphar.2019.00349. eCollection 2019.
7
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Blood Adv. 2018 Jul 10;2(13):1595-1607. doi: 10.1182/bloodadvances.2017014845.
8
Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy.
Toxics. 2015 Aug 7;3(3):322-341. doi: 10.3390/toxics3030322.
9
Neurological complications of new chemotherapy agents.
Neuro Oncol. 2018 Jan 10;20(1):24-36. doi: 10.1093/neuonc/nox115.
10
Reversible global aphasia as a side effect of quetiapine: a case report and literature review.
Neuropsychiatr Dis Treat. 2017 Aug 28;13:2257-2260. doi: 10.2147/NDT.S141273. eCollection 2017.
本文引用的文献
1
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):211-4. doi: 10.1016/j.clml.2013.11.004. Epub 2013 Nov 16.
2
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
3
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
PLoS One. 2013 Aug 5;8(8):e71754. doi: 10.1371/journal.pone.0071754. Print 2013.
4
Thalidomide-a notorious sedative to a wonder anticancer drug.
Curr Med Chem. 2013;20(33):4102-8. doi: 10.2174/09298673113209990198.
5
Immunomodulatory drugs in multiple myeloma.
Expert Rev Hematol. 2013 Feb;6(1):69-82. doi: 10.1586/ehm.12.62.
6
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23.
7
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.
Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.
8
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
J Clin Oncol. 2011 Jan 20;29(3):316-23. doi: 10.1200/JCO.2010.30.8387. Epub 2010 Dec 13.
9
Identification of a primary target of thalidomide teratogenicity.
Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319.
10
Central and peripheral nervous system toxicity of common chemotherapeutic agents.
Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7. doi: 10.1007/s00280-008-0876-6. Epub 2008 Nov 25.
Zotero 插件